SCHEMBL679110

SCHEMBL679110

Cn1ncc2cc(Oc3ccc([N+](=O)[O-])cc3F)c(C(=O)O)cc21

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SERPINE1 P05121 3/20 0.43
HSPB1 P04792 4/20 0.42
PLAU P00749 1/20 0.41
S1PR4 O95977 1/20 0.41
MAPT P10636 3/20 0.41
ALDH1A1 P00352 2/20 0.41
MAPK1 P28482 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
MAPK14 Q16539 1/20 0.40
GLS O94925 1/20 0.40
PLK4 O00444 1/20 0.38
NTRK1 P04629 1/20 0.38
RET P07949 1/20 0.38
MET P08581 1/20 0.38
AXL P30530 1/20 0.38
KDR P35968 1/20 0.38
FLT3 P36888 1/20 0.38
MST1R Q04912 1/20 0.38
DDR1 Q08345 1/20 0.38
MERTK Q12866 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL678989 0.88 MAPT (0.44) HSPB1PLAUS1PR4MAPTALDH1A1
SCHEMBL29487166 0.86 HSPB1 (0.44) SERPINE1HSPB1S1PR4MAPTALDH1A1
SCHEMBL679255 0.86 HSPB1 (0.44) SERPINE1HSPB1S1PR4MAPTALDH1A1
SCHEMBL679474 0.86 ALDH1A1 (0.44) HSPB1S1PR4MAPTALDH1A1MAPK1
SCHEMBL680514 0.81 PLK4 (0.41) SERPINE1HSPB1S1PR4MAPTALDH1A1
SCHEMBL679209 0.80 ALDH1A1 (0.39) SERPINE1HSPB1PLAUS1PR4MAPT
SCHEMBL679247 0.80 CYP11B1 (0.47) HSPB1S1PR4MAPTALDH1A1MAPK1
SCHEMBL679190 0.79 RXRA (0.43) SERPINE1HSPB1PLAUMAPTALDH1A1
SCHEMBL23081442 0.79 CCNT1 (0.42) SERPINE1HSPB1S1PR4MAPTALDH1A1
SCHEMBL680355 0.79 PLK4 (0.53) HSPB1S1PR4MAPTALDH1A1MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-RE43878-E1 Amidophenoxyindazoles useful as inhibitors of c-Met ELI LILLY AND COMPANY (US) 2012-12-25 US disclosed
EP-2310382-B1 AMIDOPHENOXYINDAZOLES USEFUL AS INHIBITORS OF C-MET LILLY CO ELI (US) 2012-02-22 EP disclosed
US-8030302-B2 Amidophenoxyindazoles useful as inhibitors of c-Met ELI LILLY AND COMPANY (US) 2011-10-04 US disclosed
EP-2310382-A1 AMIDOPHENOXYINDAZOLES USEFUL AS INHIBITORS OF C-MET Eli Lilly & Company (US) 2011-04-20 EP disclosed
WO-2010011538-A1 AMIDOPHENOXYINDAZOLES USEFUL AS INHIBITORS OF C-MET ELI LILLY AND COMPANY (US) 2010-01-28 WO disclosed
US-20100022529-A1 AMIDOPHENOXYINDAZOLES USEFUL AS INHIBITORS OF C-MET ELI LILLY AND COMPANY 2010-01-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100022529-A1 AMIDOPHENOXYINDAZOLES USEFUL AS INHIBITORS OF C-MET MET, MYCBP, MYC SERPINE1 3292/4885HSPB1 1726/4885PLAU 3172/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.